Primary Biliary Cholangitis (PBC)
Gastroenterology·MeSH: Liver Cirrhosis, Biliary
Prevalence
30.0 / 100K
3 drugs in development·3 companies·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| 2mg cs0159 | X4 Pharmaceuticals, Inc (XFOR) |
Phase 2(1)
| Drug | Company |
|---|---|
| CNP-104 | IRONWOOD PHARMACEUTICALS INC (IRWD) |
Phase 1/Phase 2(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Primary Biliary Cholangitis (PBC)?
BioSniper tracks 3 drugs in development for Primary Biliary Cholangitis (PBC) across 3 companies.
How many clinical trials target Primary Biliary Cholangitis (PBC)?
There are 2 clinical trials targeting Primary Biliary Cholangitis (PBC) tracked by BioSniper.
What is the prevalence of Primary Biliary Cholangitis (PBC)?
The estimated prevalence of Primary Biliary Cholangitis (PBC) is approximately 30.0 per 100,000 population.
Deep-dive into Primary Biliary Cholangitis (PBC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis